The science behind Restylane®
Restylane® is the original non-animal stabilized hyaluronic acid dermal filler. Restylane® provides immediate results, and to date, there have been over 50 million treatments1. The complementary range of Restylane® dermal filler treatments can be tailored to any individual look to enhance and refine facial features.
Why do people want to
refine their facial features?
An important reason for the use of dermal fillers is facial aging, a complex process that affects many parts of the face. You may lose definition and bone support due to bone resorption, especially at the posterior part of the jaw. Another consequence of aging is the loss of facial fat, leading to a loss of facial volume. In addition, fat compartments in the cheeks may descend toward the jawline, thereby affecting facial contour. Furthermore, fine lines and wrinkles may appear due to loss of collagen, hydration and elasticity. Facial dermal filler treatments with stabilized hyaluronic acid have become an important treatment alternative.
People of all ages may wish to enhance their appearance uniquely. They may want to enhance or refine their lips, cheeks, or jawline according to their own view of beauty and aesthetic aspirations. Dermal filler treatments with stabilized hyaluronic acid, including deep wrinkle fillers and facial wrinkle fillers, can be used in a way that allows them to realize their goals.
The history of hyaluronic acid dermal fillers
Upon its launch more than 25 years ago, Restylane® became the world’s first non-animal dermal filler with stabilized hyaluronic acid.
Hyaluronic acid is a native molecule that occurs naturally in our bodies. It is a polysaccharide, which can bind vast amounts of water — 1,000 times its weight. Hyaluronic acid therefore helps our bodies retain water and keeps our body tissues soft, hydrated, and flexible.
Natural hyaluronic acid in our bodies forms long molecular chains. This naturally occurring hyaluronic acid degrades quickly, within 24 - 48 hours. Restylane® dermal filler treatments contain hyaluronic acid stabilized with a cross-linking technology. The injected hyaluronic acid molecules form a three-dimensional network similar to naturally occurring hyaluronic acid, which does not degrade at the same rate. Restylane® delivers long-lasting results2.
Restylane® has become the gold standard of dermal fillers. It is the brand to which all other hyaluronic acid dermal filler brands are compared. Since its launch, there have been more than 50 million treatments with Restylane® worldwide1.
A complementary range of dermal fillers to create any look
NASHA® and OBT™ technologies are the basis of Restylane®'s dermal fillers3. The NASHA® and OBT™ technologies make Restylane® the world’s most versatile range of dermal filler treatments that allows healthcare practitioners to deliver truly individualized results4.
The Restylane® OBT™ gels are softer and more flexible. They are used to add volume in the midface, or to enhance contours for patients with thinner tissue coverage where a softer product is preferred. Restylane® OBT™ gels are also used for dynamic areas of the face such as lips, cheeks, and facial wrinkles5.
The Restylane® NASHA® gels are firmer and are used to create projection and definition. They are closer to the natural composition of hyaluronic acid than any other dermal filler on the market. They are suitable for lifting the cheeks, enhancing the jawline, or reducing the appearance of wrinkles6.
The image shows the differences in flexibility and firmness between the Restylane® dermal filler treatments, as well as differences in particle size. The varying properties provide healthcare practitioners with the freedom to create the results you expect and desire.
of patients saw improvement after treatment7
of patients were satisfied with their results8
of patients thought their results looked natural9
Are you looking for a clinic?
- Data on file (MA-39680).
- Andriopoulos B et al. Poster presented at AMWC 2019.; Data on file (MA-39364).
- OBT™ (Optimal Balance Technology) is known as XpresHAn Technology™ in the US.
- Data on file (MA-33939).; Öhrlund A. Poster presented at AMWC 2019.
- Philipp-Dormston WG et al. Dermatol Surg 2018;44(6):826-832.
- Kablik J et al. Dermatol Surg 2009;35(Suppl1):302–312.; Weiss RA et al. Dermatol Surg 2016;42:699–709.; Narins RS et al. Dermatol Surg 2011;37:644–650.
- Swift A et al. Clin Cosmet Investig Dermatol 2017;10:229–238.
- Philipp-Dormston et al. Dermatol Surg 2018;44(6):826–832.
- Rzany B et al. Dermatol Surg 2012;38:1153–1161.